BNP Paribas Financial Markets Takes $735,000 Position in Health Catalyst, Inc. (NASDAQ:HCAT)

BNP Paribas Financial Markets bought a new stake in Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 104,001 shares of the company's stock, valued at approximately $735,000. BNP Paribas Financial Markets owned about 0.17% of Health Catalyst at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. First Light Asset Management LLC grew its position in Health Catalyst by 22.0% in the 4th quarter. First Light Asset Management LLC now owns 5,241,121 shares of the company's stock worth $37,055,000 after purchasing an additional 944,631 shares during the last quarter. Impax Asset Management Group plc increased its position in shares of Health Catalyst by 7.7% during the 4th quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company's stock worth $19,442,000 after purchasing an additional 195,525 shares in the last quarter. Alyeska Investment Group L.P. boosted its position in Health Catalyst by 74.4% in the fourth quarter. Alyeska Investment Group L.P. now owns 2,019,380 shares of the company's stock valued at $14,277,000 after buying an additional 861,150 shares in the last quarter. Kennedy Capital Management LLC boosted its position in Health Catalyst by 42.7% in the fourth quarter. Kennedy Capital Management LLC now owns 1,891,000 shares of the company's stock valued at $13,369,000 after buying an additional 565,445 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in Health Catalyst by 17.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,591,565 shares of the company's stock valued at $11,252,000 after buying an additional 235,686 shares in the last quarter. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, COO Daniel Lesueur sold 16,902 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $4.52, for a total transaction of $76,397.04. Following the completion of the sale, the chief operating officer now directly owns 216,250 shares in the company, valued at approximately $977,450. The trade was a 7.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, General Counsel Benjamin Landry sold 13,827 shares of the company's stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $4.55, for a total transaction of $62,912.85. Following the completion of the transaction, the general counsel now owns 160,437 shares of the company's stock, valued at approximately $729,988.35. The trade was a 7.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 41,147 shares of company stock valued at $182,284 in the last quarter. Insiders own 2.50% of the company's stock.

Health Catalyst Trading Down 2.1%

Shares of HCAT stock traded down $0.08 on Wednesday, hitting $3.70. 39,230 shares of the company's stock traded hands, compared to its average volume of 714,997. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. Health Catalyst, Inc. has a one year low of $3.54 and a one year high of $9.24. The company's fifty day simple moving average is $4.05 and its 200 day simple moving average is $5.59. The stock has a market capitalization of $257.52 million, a price-to-earnings ratio of -2.74 and a beta of 1.56.

Analysts Set New Price Targets

A number of equities analysts have commented on HCAT shares. Canaccord Genuity Group reduced their price target on shares of Health Catalyst from $10.00 to $9.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. Evercore ISI downgraded shares of Health Catalyst from an "outperform" rating to an "inline" rating in a research note on Wednesday, April 9th. Piper Sandler dropped their price target on shares of Health Catalyst from $12.00 to $8.00 and set an "overweight" rating for the company in a research note on Tuesday, February 11th. Stifel Nicolaus increased their price objective on shares of Health Catalyst from $5.00 to $5.50 and gave the stock a "hold" rating in a research report on Thursday, May 8th. Finally, Stephens lowered their price objective on shares of Health Catalyst from $7.00 to $5.00 and set an "equal weight" rating for the company in a research report on Thursday, March 6th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Health Catalyst currently has an average rating of "Moderate Buy" and an average price target of $8.00.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.